Document Detail

The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.
MedLine Citation:
PMID:  16885368     Owner:  NLM     Status:  MEDLINE    
VX-680 is a potent inhibitor of Aurora kinases that induces the accumulation of cells with > or =4N DNA content, followed by cell death. Here, we define the role of p53 and p21(Waf1/Cip1) in cell cycle perturbations following exposure to VX-680. Endoreduplication and apoptosis in response to VX-680 are limited in A549 and MCF-7 cells expressing wild-type p53, and markedly enhanced in cells lacking p53, including those engineered to express the HPV16-E6 oncoprotein or short interfering RNA pools targeting p53. In contrast, endoreduplication and apoptosis occur in the p53 wild-type cell lines, RKO and U2OS. The difference in response to VX-680 among these cell lines correlates with the timing of induction of p21(Waf1/Cip1) and its ability to inhibit cyclin E-cdk2 activity. In A549 cells, VX-680 induces the expression of p53 and p21(Waf1/Cip1) within 24 hours, with consequent inhibition of cyclin E-cdk2, and reduction of retinoblastoma protein phosphorylation, limiting endoreduplication. In RKO and U2OS cells, the induction of p21(Waf1/Cip1) is delayed and associated with higher residual cyclin E-cdk2 kinase activity and retinoblastoma protein phosphorylation, followed by progressive endoreduplication and apoptosis. Abrogation of p21(Waf1/Cip1) expression by short interfering RNA targeting in A549 cells results in a substantial increase in the degree of endoreduplication, whereas inducible expression of p21(Waf1/Cip1) in p53-negative NCI-H1299 cells inhibits VX-680-induced endoreduplication and cell death. These data suggest that the integrity of the p53-p21(Waf1/Cip1)-dependent postmitotic checkpoint governs the response to Aurora kinase inhibition. Although cells with intact checkpoint function arrest with 4N DNA content, those with compromised checkpoint function are more likely to undergo endoreduplication followed by eventual apoptosis.
Farid Gizatullin; Yao Yao; Victor Kung; Matthew W Harding; Massimo Loda; Geoffrey I Shapiro
Related Documents :
11337548 - Methylxanthine sensitization of human colon cancer cells to 186re-labeled monoclonal an...
7529918 - Evasion of p53-mediated growth control occurs by three alternative mechanisms in transf...
17264218 - Blimp1 regulates cell growth through repression of p53 transcription.
12079428 - Diol- and triol-type ginseng saponins potentiate the apoptosis of nih3t3 cells exposed ...
23139748 - Hypoxia-induced modulation of apoptosis and bcl-2 family proteins in different cancer c...
16695988 - Stathmin is expressed by the proliferating hepatocytes during liver regeneration.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer research     Volume:  66     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-08-03     Completed Date:  2006-09-28     Revised Date:  2012-03-07    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  7668-77     Citation Subset:  IM    
Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apoptosis / drug effects
Cell Line, Tumor
Cyclin-Dependent Kinase Inhibitor p21 / biosynthesis,  genetics,  metabolism
Gene Duplication / drug effects
Mitosis / physiology
Neoplasms / drug therapy*,  enzymology,  pathology
Piperazines / pharmacology*
Protein-Serine-Threonine Kinases / antagonists & inhibitors*
RNA, Small Interfering / genetics
Retinoblastoma Protein / metabolism
Tumor Suppressor Protein p53 / biosynthesis,  genetics,  metabolism,  physiology*
Grant Support
P20 CA 90573/CA/NCI NIH HHS; R01 CA 90687/CA/NCI NIH HHS
Reg. No./Substance:
0/CDKN1A protein, human; 0/Cyclin-Dependent Kinase Inhibitor p21; 0/Piperazines; 0/RNA, Small Interfering; 0/Retinoblastoma Protein; 0/TP53 protein, human; 0/Tumor Suppressor Protein p53; 639089-54-6/VX680; EC Kinases; EC kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevent...
Next Document:  Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemother...